- PROJECT 1 A recent comprehensive analysis of outcomes among the first 1,092 patients with advanced hematologic malignancies transplanted under the auspices of current Projects 2 and 3 showed that one-fifth of patients died of graft-vs.-host disease (GVHD)-related causes. The analysis further showed that acute GVHD had no statistically significant associations with GVT effects. This suggested that avoiding acute GVHD would reduce the risk of non-relapse mortality (NRM) without increasing the risk of relapse. In contrast, chronic GVHD was highly significantly associated with GVT effects;however, this benefit was offset by NRM, which was largely due to infections occurring during the lengthy period of treatment for chronic GVHD. So the challenge is not to prevent chronic GVHD, since that might increase the risk of relapse, but to treat it more effectively so that both the duration of treatment and the associated risks of morbidity and NRM are reduced while GVT effects are maintained. The proposed studies will use a DLA-mismatched canine hematopoietic cell transplantation (HCT) model that has a long-standing track record of translating novel acute GVHD prevention and treatment into the clinic. Moreover, we have now established the only simple, reproducible, and clinically relevant large animal model of chronic GVHD. Having reproducible models of both acute GVHD and of chronic GVHD places us in a unique position to better understand, treat, and prevent GVH reactions. In these two canine models, T-cell activation occurs as it does clinically in human patients, despite standard postgrafting immunosuppression, which then results in either acute or chronic GVHD. Linked mechanistic studies will tell us about unique phenotypic and functional T-cell signatures that will be predictive of quiescence or of GVHD and might be targets of therapeutic interventions. In the current funding period, we have developed a unique set of canine- specific monoclonal antibodies (mAbs) and fusion proteins interacting with regulatory cell-surface determinants on T-cells that hold promise of enabling more-specific interventions in immune responses than have been possible with current pharmacological immunosuppression. We expect to be guided in the proposed therapeutic studies by mechanistic studies which might determine the time of upregulation of T-cell-specific antigens that have: ? Costimulatory function which may be blocked; ? Down-regulatory function that can be activated;or ? No regulatory function, but which can be used as targets for radioimmunotherapy. We believe that the proposed rational use of biologic agents to prevent acute GVHD and to treat chronic GVHD is highly novel and, moreover, that therapy successful in the canine model can be translated to benefit human patients transplanted under the auspices of Projects 2 and 3.
- PROJECT 1 This project is focused on preventing and treating potentially fatal immunological side effects that can occur after transplantation of marrow or blood stem cells in the treatment of patients with malignant diseases. The studies will be conducted in a large, preclinical animal model, which has a long track record of developing novel therapies that can be translated into the clinic.
|McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807|
|Maffini, Enrico; Anderson Jr, Larry D; Sandmaier, Brenda M et al. (2018) Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect. Haematologica 103:e252-e255|
|Li, Yawen; Hamlin, Donald K; Chyan, Ming-Kuan et al. (2018) cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS One 13:e0205135|
|Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313|
|Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54|
|Graves, Scott S; Rezvani, Andrew; Sale, George et al. (2017) A Canine Model of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 23:420-427|
|Shadman, Mazyar; Hingorani, Sangeeta; Lanum, Scott A et al. (2017) Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience. Leuk Lymphoma 58:740-742|
|Hill, Joshua A; Mayer, Bryan T; Xie, Hu et al. (2017) The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood 129:2316-2325|
|Venkataraman, G M; Kennedy, L J; Little, M-T E et al. (2017) Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90:165-170|
|McDonald, George B; Tabellini, Laura; Storer, Barry E et al. (2017) Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. Biol Blood Marrow Transplant 23:1257-1263|
Showing the most recent 10 out of 341 publications